Comparison between Free and Encapsulated Form of Epicatechin in Liposomes and In Polymeric Nanoparticles Against the Paraquat-Induced Toxicity of NRK-52E Cells
Main Article Content
Abstract
Both liposomes and polymeric nanoparticles have lately been utilized as carriers of conventionally prescribed medications with the aim of improving their activity in various ways. Epicatechin is a flavonoid with a limited bioavailability that can be found in natural sources. It is somewhat water soluble. However, because of its poor absorption and quick metabolism, it cannot function as it is expected. This work sought to enhance the pharmacokinetic features of epicatechin by encapsulating it in polylactic acid nanoparticles and liposomes. Liposomes were formed by the hydration of a lipid film to prepare large multilamellar vesicles, followed by membrane extrusion to formulate smaller unilamellar vesicles. On the other hand, polymeric nanoparticles were produced by double emulsification solvent diffusion method using polylactic acid as the polymer. Both products were then characterized for their particle size, zeta potential, drug loading, antioxidant activity, toxicity on cell lines (NRK-52E cells) and protection against paraquat oxidation. The mean particle size of liposomes was 183.8 ± 80.1 nm and for polylactic acid nanoparticles it was 350.9 ± 87.4 nm. Their surface zeta-potentials were -11.3 ± 3.93 and -32.9 ± 7.54 mV; respectively. The encapsulation of epicatechin in liposomes was 10.23 ± 1.54% and in polylactic acid nanoparticles 5.35 ± 3.35% (%encapsulation efficiency = 18.09 ± 1.95%). Microscopic images presented both sorts of nanoparticles to be sphere-shaped. Encapsulation of epicatechin into both liposomes and polylactic acid nanoparticles enhanced the % internalisation remarkably from 4.18 ± 0.03% to 27.05 ± 1.07% and 36.29 ± 0.09%; respectively. The toxicity test found all three forms not to be harmful to the NRK-52E cells within the concentration ranges tested. Examining the in vitro activity results showed that the same concentration of epicatechin in the liposomal form showed more protection against paraquat than epicatechin in its free form. Moreover, a lower epicatechin concentration was used in the polylactic acid nanoparticle form and still found to be more protective. From these results it can be concluded that epicatechin-loaded liposomes and polylactic nanoparticles offer protection to NRK-52E cells against paraquat induced toxicity.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Physicochemical characteristics and in-vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. Fang, J, et al. 1, 2005, Journal of Drug Targeting, Vol. 13, pp. 19-27.
3. Lecithin–chitosan–TPGS nanoparticles as nanocarriers of (−)-epicatechin enhanced its anticancer activity in breast cancer cells. Perez-Ruiz, A, et al. 2018, Royal Society of Chemistry, Vol. 8, pp. 34773-34782.
4. Solubility enhancement of morin and epicatechin through encapsulation in an albumin based nanoparticulate system and their anticancer activity against the MDA-MB-468 breast cancer cell line. Ghosh, P, et al. 6, 2016, Royal Society of Chemistry Advances, Vol. 103, pp. 101415-101429.
5. Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases. Ria, M and Kon , K. 2015, Academic Press, pp. 133-149.
6. Advances and Challenges of Liposome Assisted Drug Delivery. Sercombe, L, et al. 2015, Frontiers in Pharmacology, Vol. 6, p. 286.
7. Nanoescapology: Progress towards understanding the endosomal escape of polymeric nanoparticles. Selby, L, et al. 5, 2016, WIREs. Nanomadicine and nanobiotechnology, Vol. 9, p. e1452.
8. Preparation of liposomes containing small gold nanoparticles using electrostatic interactions. Dichello, G, et al. 2017, European Journal of Pharmaceutical Sciences, Vol. 105, pp. 55-63.
9. Buhecha, M, Lansley, B, Somavarapu, S, Pannala, S. (2019) Development and characterization of PLA nanoparticles for pulmonary drug delivery: Co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug. Buhecha, M, et al. 2019, Buhecha, M, Lansley, B, Somavarapu, S, Pannala, S. (2019) Development and characterization of PLA nanoparticles for pulmonary drug Journal of Drug Delivery Scien, Vol. 53, p. 101128.
10. Poly (D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane. Li, Z, et al. 2013, Journal of microencapsulation, Vol. 30, pp. 432-440.
11. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Re, R, et al. 9/10, 1998, Free Radical Biology & Medicine, Vol. 26, pp. 1231-1237.
12. Inhibition of Peroxynitrite-Mediated Tyrosine. Pannala, A, et al. 1997, Biochemical and Biophysical Research Communications, Vol. 232, pp. 164-168.
13. Measurement of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT. Abe, K and Matsuki, N. 4, 2000, Neuroscientific Research, Vol. 38, pp. 325-329.
14. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Mosmann, T. 1983, Journal of Immunological Methods, Vol. 65, pp. 55-63.
15. Protective effects of resveratrol encapsulation in liposomes or PLA nanoparticles against oxidative stress in NRK-52E cells. Layas, Kauther Ibrahim, chatterjee, PK (Charley) and Pannala, Ananth S. 1, 2022, Nanoparticles, Vol. 3, p. 9.
16. Characterisation of tea catechins-loaded nanoparticles prepared from chitosan and an edible polypeptide. Tang, D, et al. 1, 2012, Food Hydrocolloids, Vol. 30, pp. 33-41.
17. Liposomes: Aplication in Medicine. Banerjee, R. 1, 2001, Journal of Biomaterials Applications, Vol. 16, pp. 3-21.
18. Liposomal Formulations in Clinical Use: An Updated Review. Bulbake, U, et al. 2, 2017, Pharmaceutics, Vol. 9, p. 12.
19. Mayer, B. Encyclopedia of Nephrology and Acute Kidney Injury. s.l. : Foster Academics, 2015. pp. 147-163. 978-1-63242-166-1.
20. Effect of curcumin on glycerol-induced acute kidney injury in rats. Wu, J, et al. 2017, Scientific Reports, p. 10114.
21. Intensity of Renal Support in Critically Ill Patients with Acute Renal Injury. Pavlakou, P, et al. 2008, The New English Journal of Medicine, Vol. 359, pp. 7-20.
22. Liposomal Antioxidants for Protection against Oxidant-Induced Damage. Suntres, Z. 2011, Journal of Toxicology, p. 152474.
23. Cationic liposomes containing antioxidants reduces pulmonary injury in experimental model of sepsis: Liposomes antioxidants reduces pulmonary damage. Galvao, A, et al. 2016, Respiratory Physiology & Neurobiology, Vol. 231, pp. 55-62.
24. Resveratrol encapsulated in novel fusogenic liposomes activates Nrf2 and attenuates oxidative stress in cerebromicrovascular endothelial cells from aged rats. Csiszar, A, et al. 3, 2015, Resveratrol encapsulated in novel fusogenic liposomes activates Nrf2 and attenuates oxidative stThe journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 70, pp. 303-313.
25. Using liposomes as carriers for polyphenolic compounds: the case of trans-resveratrol. Bonechi, C, et al. 8, 2012, PLoS One, Vol. 7, p. e41438.
26. Resveratrol loaded liposomes produced by different techniques. Isailovi, B, et al. 2013, Innovative Food Science & Emerging Technologies, Vol. 19, pp. 181-189.
27. Plant foods and herbal sources of resveratrol. Burns, J, et al. 11, 2002, Journal of agricultural and food chemistry, Vol. 50, pp. 3337-3340.
28. Resveratrol Levels and All-Cause Mortality in Older Community-Dwelling Adults. Semba, R, Ferrucci, L and Bartali, B. 7, 2014, JAMA Internal Medicine, Vol. 174, pp. 1077-1084.
29. Preparation, Characterization, and Evaluation of Liposomal Ferulic Acid In Vitro and In Vivo. Qin, J, et al. 6, 2008, Drug Development and Industrial Pharmacy, Vol. 34, pp. 602-608.
30. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway. He, X, et al. 1, 2012, The Journal of Pharamcology and Experimental Therapeutics, Vol. 342, pp. 81-90.
31. In vitro antioxidant and antitumor study of zein/SHA nanoparticles loaded with resveratrol . Shi, Q, et al. 2021, Foofd Science and Nutrition, pp. 1-8.
32. Resveratrol loaded nanoparticles induce antioxidant activity against oxidative stress. Kim, J, et al. 2, 2016, The Asian-Australasian Association of Animal Production Societies, Vol. 29, pp. 288-298.
33. Improving solubility, stability, and cellular uptake of resveratrol by nanoencapsulation with chitosan and gamma-poly (glutamic acid). Jeon , Y, Lee, J and Lee, H. 2016, Colloids and Surfaces B: Bionterfaces, Vol. 147, pp. 224-233.
34. Liu, B and Hu, X. Hollow micro- and nanomaterials: Synthesis and applications. [book auth.] Q Zhao. Micro and Nano Technologies. Advanced Nanomaterials for Pollutant Sensing and Environmental Catalysis. s.l. : Elsevier, 2020, pp. 1-38.
35. Resveratrol-loaded polymeric nanoparticles: Validation of an HPLC-PDA method to determine the drug entrapment and evalution of its antioxidant activity. Lindner, G, Khalil, N and Mainardes, R. 2013, The Scientific World Journal, p. 506083.
36. Resveratrol-loaded albumin nanoparticles with prolonged blood circulation and improved biocompatibility for high effective targeted pancreatic tumour therapy. Geng, T, et al. 2017, Nanoscale Research Letters, p. 437.
37. Increased oral bioavailability of resveratrol by its encapsulation in casein nanoparticles. Penalva, R, et al. 9, 2018, International Journal of Molecular Sciences, Vol. 19, p. 2816.
38. Potential adverse effects of resveratrol: A litrature review. Shaito, A, et al. 6, 2020, Internation Journal of Molecular Sciences, Vol. 21, p. 2084.
39. Resveratrol-associated renal toxicity. Crowell, J, et al. 2, 2004, Toxicological Science, Vol. 82, pp. 614-619.
40. Resveratrol nanoparticles: A promising therapeuitic advancment over native resveratrol. Chung, I, et al. 4, 2020, Processes, Vol. 8, p. 458.
41. A review on phospholipids and their main applications in drug delivery systems. Li, J, et al. 2, 2015, Asian Journal of Pharmaceutical Sciences, Vol. 10, pp. 81-98.
42. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. Campbell, R, Balasubramanian, S and Straubinger, R. 2000, Jouranl of Pharmaceutical Sciences, Vol. 90, pp. 1091-1105.
43. Evaluation of extrusion technique for nanosizing liposomes. Ong, S, et al. 4, 2016, Pharmaceutics, Vol. 8, p. 36.
44. Hope, M, et al. Reduction of lipsome size and preparation of unilamellar vesicles by extrusion techniques. [book auth.] G Gregoriadis. Liposome technology. s.l. : CRC Press, 1993, pp. 123-126.
45. Physiochemical characteristics and in-vivo deposition of liposome-encapsulated tea catechins by topical and intratumor adminstrations. Fang, J, et al. 1, 2005, Journal of Drug Targeting, Vol. 13, pp. 19-27.
46. Effect of lipsome encapsulation of tea catechins on their accumat. Fang, J, et al.